Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
221 Leser
Artikel bewerten:
(0)

Celegence Partners With Performance Development Group to Help Life Sciences Companies Maximize Their RIMS ROI

Strategic partnership allows life sciences companies to achieve value in their RIMS investments through state-of-the-art learning methodologies and regulatory affairs business process expertise

DOWNERS GROVE, IL., March 13, 2019 /PRNewswire/ -- Celegence, a global regulatory affairs services and solution provider, today announced a strategic partnership with Performance Development Group (PDG), a managed learning solution company providing end-to-end learning solutions. The partnership combines Celegence's regulatory business process expertise with PDG's learning solution knowledge, delivering clients the skills, quality and commitment to innovation needed to train global users on RIMS (regulatory information management systems).

Celegence's in-depth knowledge of regulatory business processes and expertise in managing data in RIMS on behalf of clients combined with PDG's unique tailored learning methodology creates a unique and winning combination. The expertise of both companies was underscored recently when a top-five global pharmaceutical company selected Celegence and PDG to design, develop, and deliver RIMS training to more than 5000 global users.

"Celegence's expertise in regulatory affairs make them an obvious choice for a partnership with Performance Development Group," says PDG's Managing Partner David Manning. "They have a strong and proven record in both solution and business operations expertise, and our capabilities will complement theirs in providing RIMS training."

Celegence and PDG will work with life sciences companies to help them maximize the ROI of their RIMS investment by ensuring that users are fully prepared to leverage their systems' benefits. Through the partnership, the companies will also help clients to harmonize the data in their systems so can be leveraged for reporting and analytics. In addition, the global RIMS training program helps clients clarify roles and responsibilities to multiple user communities.

"Celegence and PDG are partnering with the long-term objective to support both mid and large life sciences companies to achieve continuous process improvement for regulatory affairs throughout their global RIMS journey," says Sonia Veluchamy, CEO of Celegence. "We are confident in our ability to support the industry by combining our subject matter expertise and investment in technology innovations."

Learn More: Celegence Learning Management

About Celegence

Celegence helps life sciences companies navigate complex global regulatory requirements by providing consulting services and solutions dedicated to regulatory affairs. Celegence supports life sciences customers in the areas of regulatory intelligence, RIMS, publishing, labelling, medical writing and compliance toward new regulations for different product portfolios. Celegence's depth of experience and extensive delivery capability allows regulatory affairs teams to operate more efficiently, reduce cost, and improve compliance. For more information, visit www.celegence.com or follow Celegence on LinkedIn and Twitter.

About Performance Development Group

PDG accelerates achievement of client business goals through the design, implementation, and ongoing management of services and solutions to create lasting improvement in the performance of each company's people. With more than 16 years of proven experience, PDG is a recognized industry leader in addressing the difficult challenges associated with executing business strategy by improving human behavior. For more information, visit https://www.performdev.com/, or follow PDG on LinkedIn and Twitter.

Media Contact:
info@Celegence.com

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.